Merck SG&A Expenses 2010-2024 | MRK

Merck sg&a expenses for the twelve months ending September 30, 2024 were $10.757B, a 3.56% increase year-over-year.

  • Merck annual sg&a expenses for 2023 were $10.504B, a 4.6% increase from 2022.
  • Merck annual sg&a expenses for 2022 were $10.042B, a 4.24% increase from 2021.
  • Merck annual sg&a expenses for 2021 were $9.634B, a 7.58% increase from 2020.

Merck SG&A Expenses 2010-2024 | MRK

  • Merck annual sg&a expenses for 2023 were $10.504B, a 4.6% increase from 2022.
  • Merck annual sg&a expenses for 2022 were $10.042B, a 4.24% increase from 2021.
  • Merck annual sg&a expenses for 2021 were $9.634B, a 7.58% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$757B
Novo Nordisk (NVO)$483B
Johnson & Johnson (JNJ)$377.3B
AbbVie (ABBV)$354.3B
Novartis AG (NVS)$218.9B
AstraZeneca (AZN)$200.6B
Pfizer (PFE)$155.6B
Sanofi (SNY)$131.3B
Innoviva (INVA)$1.3B